SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gene Therapeutics & RNAi

PUBLISHER: Visiongain | PRODUCT CODE: 2151277

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 2151277

Global mRNA Contract Manufacturing Market Report 2026-2036

PUBLISHED:
PAGES: 378 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5916
PDF (Team License - Up to 6 Users)
USD 7004
PDF (Site License)
USD 8228
PDF (Enterprise License - Includes Free Datasets)
USD 10397.20

Add to Cart

Description

Table of Contents

List of Tables

This report provides a comprehensive analysis of the market including market size, growth drivers, competitive positioning, and revenue forecasts across development stage, service type, and end-user segments.

Expanding Pipeline Beyond COVID-19 Vaccines

The mRNA pipeline is diversifying beyond COVID-19 vaccines into cancer vaccines and immunotherapies, vaccines for other infectious diseases, protein-replacement therapies, gene editing, cell reprogramming and regenerative medicine. This expansion broadens the addressable market for contract manufacturers while introducing more varied production, formulation and analytical requirements.

Each programme may require support across DNA-template production, in-vitro transcription, purification, LNP formulation, analytical testing and GMP manufacturing. Many candidates remain in preclinical or early clinical development, where biotechnology companies frequently lack dedicated manufacturing infrastructure. External partners therefore provide access to specialist teams, flexible capacity and established quality systems. As successful candidates advance into later-stage trials, demand will extend to process validation, larger manufacturing campaigns, regulatory support and commercial-readiness planning.

Report Scope and Data Coverage

  • Global mRNA contract manufacturing market analysis
  • Revenue forecasts to 2036 with annual growth estimates
  • Segment-level modelling across development stage, service type, and end-user
  • Regional and national market forecasts across five regions and 14 leading national markets
  • Competitive intelligence on 15 leading companies

Includes both quantitative forecasting and qualitative strategic analysis covering technology, competition, trade dynamics, and supply chain developments.

Our 300-page report provides 107 tables and 148 charts/graphs.

Segmentation Framework

By Development Stage

  • Preclinical
  • Clinical
  • Commercial

By Service Type

  • Plasmid DNA Template Development and Manufacturing
  • mRNA Drug Substance Manufacturing
  • Formulation and Lipid Nanoparticle Encapsulation
  • Process Development and Tech Transfer
  • Fill-Finish and Packaging
  • Analytical Development
  • Others

By End-User

  • Government and Academic Institutes
  • Pharmaceutical Companies
  • Biotech Companies
  • Others

Geographic Coverage

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East and Africa

  • GCC
  • South Africa
  • Rest of MEA

Company Intelligence Coverage

This report includes detailed profiles of 15 leading companies, including:

  • AGC Biologics
  • BioCina Pty Ltd.
  • Biomay AG
  • Bio-Synthesis, Inc.
  • Catalent, Inc. (Novo Holdings)
  • Curia Global, Inc.
  • Danaher Corporation (Aldevron)
  • Evonik Industries AG
  • Kaneka Eurogentec S.A.
  • Lonza Group AG
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • Thermo Fisher Scientific Inc. (Patheon Pharma Services)
  • TriLink BioTechnologies (Maravai LifeSciences)
  • Wacker Biotech GmbH

Each profile includes:

  • Business overview
  • Financial and market positioning
  • Technology roadmap and programme wins
  • Strategic outlook

Key Questions Answered

  • How is the mRNA contract manufacturing market evolving?
  • What is driving and restraining the market?
  • How will each submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2036?
  • How will the market shares for each submarket develop from 2026 to 2036?
  • Will leading national markets broadly follow macroeconomic dynamics, or will individual markets outperform others?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the industry evolve during the period between 2026 and 2036?

Bespoke Intelligence and Customisation

Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements. This includes:

  • Custom market segmentation and forecasts
  • Competitive benchmarking and strategy analysis
  • Supply chain and sourcing intelligence
  • LNP formulation and mRNA manufacturing capability assessment
  • Scenario modelling including tariffs and geopolitical risk

Why This Market Intelligence Matters

The mRNA contract manufacturing market is entering a period of sustained structural growth as the pipeline diversifies, commercial programmes accumulate, and pharmaceutical and biotechnology companies increasingly rely on specialist CDMOs for integrated manufacturing services spanning template production, drug substance, LNP formulation, and sterile fill-finish.

CDMOs that combine technical breadth across the full mRNA manufacturing chain, flexible capacity for rapid programme onboarding, and strong analytical and regulatory capabilities are best positioned to capture long-term value over the next decade.

Show more
Product Code: PHA1399

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to mRNA Contract Manufacturing Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Impact Analysis
  • 3.3 Market Driving Factors
  • 3.4 Market Restraining Factors
  • 3.5 Market Opportunities
  • 3.6 Porter's Five Forces Analysis
    • 3.6.1 Bargaining Power of Suppliers
    • 3.6.2 Bargaining Power of Buyers
    • 3.6.3 Competitive Rivalry
    • 3.6.4 Threat of Substitutes
    • 3.6.5 Threat of New Entrants
  • 3.7 PEST Analysis
  • 3.8 U.S. Tariffs: What's the Impact on Global mRNA Contract Manufacturing Market?
    • 3.8.1 Overview
    • 3.8.2 V-Shaped Recovery Scenario
      • 3.8.2.1 Why V-Shaped Recovery?
      • 3.8.2.2 Impact from Tariffs
      • 3.8.2.3 Market Dynamics and Demand Recovery
      • 3.8.2.4 Policy and Funding Support
      • 3.8.2.5 Timeframe for Recovery
  • 3.9 U-Shaped Recovery Scenario
      • 3.9.1.1 Why U-Shaped Recovery?
      • 3.9.1.2 Impact from Tariffs
      • 3.9.1.3 Market Dynamics and Demand Recovery
      • 3.9.1.4 Policy and Funding Support
      • 3.9.1.5 Timeframe for Recovery
  • 3.10 L Shaped Recovery Scenario
      • 3.10.1.1 Why L-Shaped Recovery?
      • 3.10.1.2 Impact from Tariffs
      • 3.10.1.3 Market Dynamics and Demand Recovery
      • 3.10.1.4 Policy and Funding Support
      • 3.10.1.5 Timeframe for Recovery
  • 3.11 What Strategic Considerations Should Clients Factor into Their Near-term (2026-2031) and Long-term (2026-2036) Planning?
  • 3.12 Impact of U.S. and China Trade War on mRNA Contract Manufacturing Market
  • 3.13 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?

4 mRNA Contract Manufacturing Market Analysis by Development Stage (US$ Million, AGR %)

  • 4.1 Key Findings
  • 4.2 Development Stage Segment: Market Attractiveness Index
  • 4.3 Preclinical
    • 4.3.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.3.2 Market Share by Region, 2026 & 2036 (%)
  • 4.4 Clinical
    • 4.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.4.2 Market Share by Region, 2026 & 2036 (%)
  • 4.5 Commercial
    • 4.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.5.2 Market Share by Region, 2026 & 2036 (%)

5 mRNA Contract Manufacturing Market Analysis by Service Type (US$ Million, AGR %)

  • 5.1 Key Findings
  • 5.2 Service Type Segment: Market Attractiveness Index
  • 5.3 Plasmid DNA Template Development and Manufacturing
    • 5.3.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.3.2 Market Share by Region, 2026 & 2036 (%)
  • 5.4 mRNA Drug Substance Manufacturing
    • 5.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.4.2 Market Share by Region, 2026 & 2036 (%)
  • 5.5 Formulation and Lipid Nanoparticle Encapsulation
    • 5.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.5.2 Market Share by Region, 2026 & 2036 (%)
  • 5.6 Process Development and Tech Transfer
    • 5.6.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.6.2 Market Share by Region, 2026 & 2036 (%)
  • 5.7 Fill-Finish and Packaging
    • 5.7.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.7.2 Market Share by Region, 2026 & 2036 (%)
  • 5.8 Analytical Development
    • 5.8.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.8.2 Market Share by Region, 2026 & 2036 (%)
  • 5.9 Others
    • 5.9.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.9.2 Market Share by Region, 2026 & 2036 (%)

6 mRNA Contract Manufacturing Market Analysis by End-users (US$ Million, AGR %)

  • 6.1 Key Findings
  • 6.2 End-users Segment: Market Attractiveness Index
  • 6.3 Government and Academic Institutes
    • 6.3.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.3.2 Market Share by Region, 2026 & 2036 (%)
  • 6.4 Pharmaceutical Companies
    • 6.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.4.2 Market Share by Region, 2026 & 2036 (%)
  • 6.5 Biotech Companies
    • 6.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.5.2 Market Share by Region, 2026 & 2036 (%)
  • 6.6 Others
    • 6.6.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.6.2 Market Share by Region, 2026 & 2036 (%)

7 mRNA Contract Manufacturing Market Analysis by Region

  • 7.1 Key Findings
  • 7.2 Regional Market Size Estimation and Forecast

8 North America mRNA Contract Manufacturing Market Analysis

  • 8.1 Key Findings
  • 8.2 North America mRNA Contract Manufacturing Market Attractiveness Index
  • 8.3 North America mRNA Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 8.4 North America mRNA Contract Manufacturing Market Size Estimation and Forecast by Country
  • 8.5 North America mRNA Contract Manufacturing Market Size Estimation and Forecast by Development Stage
  • 8.6 North America mRNA Contract Manufacturing Market Size Estimation and Forecast by Service Type
  • 8.7 North America mRNA Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 8.8 U.S. mRNA Contract Manufacturing Market Analysis
  • 8.9 Canada mRNA Contract Manufacturing Market Analysis

9 Europe mRNA Contract Manufacturing Market Analysis

  • 9.1 Key Findings
  • 9.2 Europe mRNA Contract Manufacturing Market Attractiveness Index
  • 9.3 Europe mRNA Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 9.4 Europe mRNA Contract Manufacturing Market Size Estimation and Forecast by Country
  • 9.5 Europe mRNA Contract Manufacturing Market Size Estimation and Forecast by Development Stage
  • 9.6 Europe mRNA Contract Manufacturing Market Size Estimation and Forecast by Service Type
  • 9.7 Europe mRNA Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 9.8 Germany mRNA Contract Manufacturing Market Analysis
  • 9.9 UK mRNA Contract Manufacturing Market Analysis
  • 9.10 France mRNA Contract Manufacturing Market Analysis
  • 9.11 Italy mRNA Contract Manufacturing Market Analysis
  • 9.12 Rest of Europe mRNA Contract Manufacturing Market Analysis
    • 9.12.1 Rest of Europe mRNA Contract Manufacturing Market Forecast by Development Stage, 2026-2036 (US$ Million, AGR%)

10 Asia Pacific mRNA Contract Manufacturing Market Analysis

  • 10.1 Key Findings
  • 10.2 Asia Pacific mRNA Contract Manufacturing Market Attractiveness Index
  • 10.3 Asia Pacific mRNA Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 10.4 Asia Pacific mRNA Contract Manufacturing Market Size Estimation and Forecast by Country
  • 10.5 Asia Pacific mRNA Contract Manufacturing Market Size Estimation and Forecast by Development Stage
  • 10.6 Asia Pacific mRNA Contract Manufacturing Market Size Estimation and Forecast by Service Type
  • 10.7 Asia Pacific mRNA Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 10.8 Japan mRNA Contract Manufacturing Market Analysis
  • 10.9 China mRNA Contract Manufacturing Market Analysis
  • 10.10 India mRNA Contract Manufacturing Market Analysis
  • 10.11 Australia mRNA Contract Manufacturing Market Analysis
  • 10.12 Rest of Asia Pacific mRNA Contract Manufacturing Market Analysis

11 Latin America mRNA Contract Manufacturing Market Analysis

  • 11.1 Key Findings
  • 11.2 Latin America mRNA Contract Manufacturing Market Attractiveness Index
  • 11.3 Latin America mRNA Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 11.4 Latin America mRNA Contract Manufacturing Market Size Estimation and Forecast by Country
  • 11.5 Latin America mRNA Contract Manufacturing Market Size Estimation and Forecast by Development Stage
  • 11.6 Latin America mRNA Contract Manufacturing Market Size Estimation and Forecast by Service Type
  • 11.7 Latin America mRNA Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 11.8 Brazil mRNA Contract Manufacturing Market Analysis
  • 11.9 Mexico mRNA Contract Manufacturing Market Analysis
  • 11.10 Rest of Latin America mRNA Contract Manufacturing Market Analysis

12 MEA mRNA Contract Manufacturing Market Analysis

  • 12.1 Key Findings
  • 12.2 MEA mRNA Contract Manufacturing Market Attractiveness Index
  • 12.3 MEA mRNA Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 12.4 MEA mRNA Contract Manufacturing Market Size Estimation and Forecast by Country
  • 12.5 MEA mRNA Contract Manufacturing Market Size Estimation and Forecast by Development Stage
  • 12.6 MEA mRNA Contract Manufacturing Market Size Estimation and Forecast by Service Type
  • 12.7 MEA mRNA Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 12.8 GCC mRNA Contract Manufacturing Market Analysis
  • 12.9 South Africa mRNA Contract Manufacturing Market Analysis
  • 12.10 Rest of MEA mRNA Contract Manufacturing Market Analysis

13 Company Profiles

  • 13.1 AGC Biologics
    • 13.1.1 Company Snapshot
    • 13.1.2 Company Overview
    • 13.1.3 Company Financials
      • 13.1.3.1 Revenue, 2022-2025 (US$ Million)
      • 13.1.3.2 R&D, 2022-2025 (US$ Million)
      • 13.1.3.3 Business Segment Market Shares (%), 2025
      • 13.1.3.4 Geographic Segment Market Shares (%), 2025
    • 13.1.4 Service Benchmarking
    • 13.1.5 Strategic Outlook
  • 13.2 BioCina Pty Ltd.
    • 13.2.1 Company Snapshot
    • 13.2.2 Company Overview
    • 13.2.3 Company Financials
      • 13.2.3.1 Revenue, 2022-2025 (US$ Million)
      • 13.2.3.2 R&D, 2022-2025 (US$ Million)
      • 13.2.3.3 Business Segment Market Shares (%), 2025
      • 13.2.3.4 Geographic Segment Market Shares (%), 2025
    • 13.2.4 Service Benchmarking
    • 13.2.5 Strategic Outlook
  • 13.3 Biomay AG
    • 13.3.1 Company Snapshot
    • 13.3.2 Company Overview
    • 13.3.3 Company Financials
      • 13.3.3.1 Revenue, 2022-2025 (US$ Million)
      • 13.3.3.2 R&D, 2022-2025 (US$ Million)
      • 13.3.3.3 Business Segment Market Shares (%), 2025
      • 13.3.3.4 Geographic Segment Market Shares (%), 2025
    • 13.3.4 Service Benchmarking
    • 13.3.5 Strategic Outlook
  • 13.4 Bio-Synthesis, Inc.
    • 13.4.1 Company Snapshot
    • 13.4.2 Company Overview
    • 13.4.3 Company Financials
      • 13.4.3.1 Revenue, 2022-2025 (US$ Million)
      • 13.4.3.2 R&D, 2022-2025 (US$ Million)
      • 13.4.3.3 Business Segment Market Shares (%), 2025
      • 13.4.3.4 Geographic Segment Market Shares (%), 2025
    • 13.4.4 Service Benchmarking
    • 13.4.5 Strategic Outlook
  • 13.5 Catalent, Inc. (Novo Holdings)
    • 13.5.1 Company Snapshot
    • 13.5.2 Company Overview
    • 13.5.3 Company Financials
      • 13.5.3.1 Revenue, 2022-2025 (US$ Million)
      • 13.5.3.2 R&D, 2022-2025 (US$ Million)
      • 13.5.3.3 Business Segment Market Shares (%), 2025
      • 13.5.3.4 Geographic Segment Market Shares (%), 2025
    • 13.5.4 Service Benchmarking
    • 13.5.5 Strategic Outlook
  • 13.6 Curia Global, Inc.
    • 13.6.1 Company Snapshot
    • 13.6.2 Company Overview
    • 13.6.3 Company Financials
      • 13.6.3.1 Revenue, 2022-2025 (US$ Million)
      • 13.6.3.2 R&D, 2022-2025 (US$ Million)
      • 13.6.3.3 Business Segment Market Shares (%), 2025
      • 13.6.3.4 Geographic Segment Market Shares (%), 2025
    • 13.6.4 Service Benchmarking
    • 13.6.5 Strategic Outlook
  • 13.7 Danaher Corporation (Aldevron)
    • 13.7.1 Company Snapshot
    • 13.7.2 Company Overview
    • 13.7.3 Company Financials
      • 13.7.3.1 Revenue, 2022-2025 (US$ Million)
      • 13.7.3.2 R&D, 2022-2025 (US$ Million)
      • 13.7.3.3 Business Segment Market Shares (%), 2025
      • 13.7.3.4 Geographic Segment Market Shares (%), 2025
    • 13.7.4 Service Benchmarking
    • 13.7.5 Strategic Outlook
  • 13.8 Evonik Industries AG
    • 13.8.1 Company Snapshot
    • 13.8.2 Company Overview
    • 13.8.3 Company Financials
      • 13.8.3.1 Revenue, 2022-2025 (US$ Million)
      • 13.8.3.2 R&D, 2022-2025 (US$ Million)
      • 13.8.3.3 Business Segment Market Shares (%), 2025
      • 13.8.3.4 Geographic Segment Market Shares (%), 2025
    • 13.8.4 Service Benchmarking
    • 13.8.5 Strategic Outlook
  • 13.9 Kaneka Eurogentec S.A.
    • 13.9.1 Company Snapshot
    • 13.9.2 Company Overview
    • 13.9.3 Company Financials
      • 13.9.3.1 Revenue, 2022-2025 (US$ Million)
      • 13.9.3.2 R&D, 2022-2025 (US$ Million)
      • 13.9.3.3 Business Segment Market Shares (%), 2025
      • 13.9.3.4 Geographic Segment Market Shares (%), 2025
    • 13.9.4 Service Benchmarking
    • 13.9.5 Strategic Outlook
  • 13.10 Lonza Group AG
    • 13.10.1 Company Snapshot
    • 13.10.2 Company Overview
    • 13.10.3 Company Financials
      • 13.10.3.1 Revenue, 2022-2025 (US$ Million)
      • 13.10.3.2 R&D, 2022-2025 (US$ Million)
      • 13.10.3.3 Business Segment Market Shares (%), 2025
      • 13.10.3.4 Geographic Segment Market Shares (%), 2025
    • 13.10.4 Service Benchmarking
    • 13.10.5 Strategic Outlook
  • 13.11 Recipharm AB
    • 13.11.1 Company Snapshot
    • 13.11.2 Company Overview
    • 13.11.3 Company Financials
      • 13.11.3.1 Revenue, 2022-2025 (US$ Million)
      • 13.11.3.2 R&D, 2022-2025 (US$ Million)
      • 13.11.3.3 Business Segment Market Shares (%), 2025
      • 13.11.3.4 Geographic Segment Market Shares (%), 2025
    • 13.11.4 Service Benchmarking
    • 13.11.5 Strategic Outlook
  • 13.12 Samsung Biologics Co., Ltd.
    • 13.12.1 Company Snapshot
    • 13.12.2 Company Overview
    • 13.12.3 Company Financials
      • 13.12.3.1 Revenue, 2022-2025 (US$ Million)
      • 13.12.3.2 R&D, 2022-2025 (US$ Million)
      • 13.12.3.3 Business Segment Market Shares (%), 2025
      • 13.12.3.4 Geographic Segment Market Shares (%), 2025
    • 13.12.4 Service Benchmarking
    • 13.12.5 Strategic Outlook
  • 13.13 Thermo Fisher Scientific Inc. (Patheon Pharma Services)
    • 13.13.1 Company Snapshot
    • 13.13.2 Company Overview
    • 13.13.3 Company Financials
      • 13.13.3.1 Revenue, 2022-2025 (US$ Million)
      • 13.13.3.2 R&D, 2022-2025 (US$ Million)
      • 13.13.3.3 Business Segment Market Shares (%), 2025
      • 13.13.3.4 Geographic Segment Market Shares (%), 2025
    • 13.13.4 Service Benchmarking
    • 13.13.5 Strategic Outlook
  • 13.14 TriLink BioTechnologies (Maravai LifeSciences)
    • 13.14.1 Company Snapshot
    • 13.14.2 Company Overview
    • 13.14.3 Company Financials
      • 13.14.3.1 Revenue, 2022-2025 (US$ Million)
      • 13.14.3.2 R&D, 2022-2025 (US$ Million)
      • 13.14.3.3 Business Segment Market Shares (%), 2025
      • 13.14.3.4 Geographic Segment Market Shares (%), 2025
    • 13.14.4 Service Benchmarking
    • 13.14.5 Strategic Outlook
  • 13.15 Wacker Biotech GmbH
    • 13.15.1 Company Snapshot
    • 13.15.2 Company Overview
    • 13.15.3 Company Financials
      • 13.15.3.1 Revenue, 2022-2025 (US$ Million)
      • 13.15.3.2 R&D, 2022-2025 (US$ Million)
      • 13.15.3.3 Business Segment Market Shares (%), 2025
      • 13.15.3.4 Geographic Segment Market Shares (%), 2025
    • 13.15.4 Service Benchmarking
    • 13.15.5 Strategic Outlook

14 Conclusion and Recommendations

  • 14.1 Concluding Remarks from Visiongain
  • 14.2 Recommendations for Market Players
Show more
Product Code: PHA1399

List of Tables

  • Table 1 mRNA Contract Manufacturing Market Snapshot, 2026 & 2036 (US$ Million, CAGR %)
  • Table 2 mRNA Contract Manufacturing Market Forecast by Development Stage, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 3 Preclinical Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 4 Clinical Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 5 Commercial Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 6 mRNA Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 7 Plasmid DNA Template Development and Manufacturing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 8 mRNA Drug Substance Manufacturing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 9 Formulation and Lipid Nanoparticle Encapsulation Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 10 Process Development and Tech Transfer Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 11 Fill-Finish and Packaging: Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 12 Analytical Development Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 13 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 14 mRNA Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 15 Government and Academic Institutes Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 16 Pharmaceutical Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 17 Biotech Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 18 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 19 mRNA Contract Manufacturing Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 20 North America mRNA Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 21 North America mRNA Contract Manufacturing Market Forecast by Development Stage, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 22 North America mRNA Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 23 North America mRNA Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 24 U.S. mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 25 Canada mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 26 Europe mRNA Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 27 Europe mRNA Contract Manufacturing Market Forecast by Development Stage, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 28 Europe mRNA Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 29 Europe mRNA Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 30 Germany mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 31 UK mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 32 France mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 33 Italy mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 34 Spain mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 35 Russia mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 36 Rest of Europe mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 37 Asia Pacific mRNA Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 38 Asia Pacific mRNA Contract Manufacturing Market Forecast by Development Stage, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 39 Asia Pacific mRNA Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 40 Asia Pacific mRNA Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 41 Japan mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 42 China mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 43 India mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 44 Australia mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 45 South Korea mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 46 Rest of Asia Pacific mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 47 Latin America mRNA Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 48 Latin America mRNA Contract Manufacturing Market Forecast by Development Stage, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 49 Latin America mRNA Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 50 Latin America mRNA Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 51 Brazil mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 52 Mexico mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 53 Argentina mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 54 Colombia mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 55 Rest of Latin America mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 56 MEA mRNA Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 57 MEA mRNA Contract Manufacturing Market Forecast by Development Stage, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 58 MEA mRNA Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 59 MEA mRNA Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 60 GCC mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 61 South Africa mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 62 Rest of MEA mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 63 AGC Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 64 AGC Biologics: Service Benchmarking
  • Table 65 AGC Biologics: Strategic Outlook
  • Table 66 BioCina Pty Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 67 BioCina Pty Ltd.: Service Benchmarking
  • Table 68 BioCina Pty Ltd.: Strategic Outlook
  • Table 69 Biomay AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 70 Biomay AG: Service Benchmarking
  • Table 71 Biomay AG: Strategic Outlook
  • Table 72 Bio-Synthesis, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 73 Bio-Synthesis, Inc.: Service Benchmarking
  • Table 74 Bio-Synthesis, Inc.: Strategic Outlook
  • Table 75 Catalent, Inc. (Novo Holdings): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 76 Catalent, Inc. (Novo Holdings): Service Benchmarking
  • Table 77 Catalent, Inc. (Novo Holdings): Strategic Outlook
  • Table 78 Curia Global, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 79 Curia Global, Inc.: Service Benchmarking
  • Table 80 Curia Global, Inc.: Strategic Outlook
  • Table 81 Danaher Corporation (Aldevron): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 82 Danaher Corporation (Aldevron): Service Benchmarking
  • Table 83 Danaher Corporation (Aldevron): Strategic Outlook
  • Table 84 Evonik Industries AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 85 Evonik Industries AG: Service Benchmarking
  • Table 86 Evonik Industries AG: Strategic Outlook
  • Table 87 Kaneka Eurogentec S.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 Kaneka Eurogentec S.A.: Service Benchmarking
  • Table 89 Kaneka Eurogentec S.A.: Strategic Outlook
  • Table 90 Lonza Group AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 91 Lonza Group AG: Service Benchmarking
  • Table 92 Lonza Group AG: Strategic Outlook
  • Table 93 Recipharm AB: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 94 Recipharm AB: Service Benchmarking
  • Table 95 Recipharm AB: Strategic Outlook
  • Table 96 Samsung Biologics Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 Samsung Biologics Co., Ltd.: Service Benchmarking
  • Table 98 Samsung Biologics Co., Ltd.: Strategic Outlook
  • Table 99 Thermo Fisher Scientific Inc. (Patheon Pharma Services): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 Thermo Fisher Scientific Inc. (Patheon Pharma Services): Service Benchmarking
  • Table 101 Thermo Fisher Scientific Inc. (Patheon Pharma Services): Strategic Outlook
  • Table 102 TriLink BioTechnologies (Maravai LifeSciences): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 103 TriLink BioTechnologies (Maravai LifeSciences): Service Benchmarking
  • Table 104 TriLink BioTechnologies (Maravai LifeSciences): Strategic Outlook
  • Table 105 Wacker Biotech GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 106 Wacker Biotech GmbH: Service Benchmarking
  • Table 107 Wacker Biotech GmbH: Strategic Outlook

List of Figures

  • Figure 1 mRNA Contract Manufacturing Market Segmentation
  • Figure 2 mRNA Contract Manufacturing Market by Development Stage: Market Attractiveness Index
  • Figure 3 mRNA Contract Manufacturing Market by Service Type: Market Attractiveness Index
  • Figure 4 mRNA Contract Manufacturing Market by End-users: Market Attractiveness Index
  • Figure 5 mRNA Contract Manufacturing Market Attractiveness Index by Region
  • Figure 6 mRNA Contract Manufacturing Market: Market Dynamics
  • Figure 7 mRNA Contract Manufacturing Market: Porter's Five Forces Analysis
  • Figure 8 mRNA Contract Manufacturing Market: PEST Analysis
  • Figure 9 mRNA Contract Manufacturing Market Attractiveness Index by Development Stage
  • Figure 10 mRNA Contract Manufacturing Market Forecast by Development Stage, 2026-2036 (US$ Million, AGR %)
  • Figure 11 mRNA Contract Manufacturing Market Share Forecast by Development Stage, 2026, 2031, 2036 (%)
  • Figure 12 Preclinical Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 13 Preclinical Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 14 Clinical Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 15 Clinical Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 16 Commercial Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 17 Commercial Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 18 mRNA Contract Manufacturing Market Attractiveness Index by Service Type
  • Figure 19 mRNA Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 20 mRNA Contract Manufacturing Market Share Forecast by Service Type, 2026, 2031, 2036 (%)
  • Figure 21 Plasmid DNA Template Development and Manufacturing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 22 Plasmid DNA Template Development and Manufacturing Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 23 mRNA Drug Substance Manufacturing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 24 mRNA Drug Substance Manufacturing Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 25 Formulation and Lipid Nanoparticle Encapsulation Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 26 Formulation and Lipid Nanoparticle Encapsulation Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 27 Process Development and Tech Transfer Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 28 Process Development and Tech Transfer Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 29 Fill-Finish and Packaging: Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 30 Fill-Finish and Packaging: Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 31 Analytical Development Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 32 Analytical Development Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 33 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 34 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 35 mRNA Contract Manufacturing Market Attractiveness Index by End-users
  • Figure 36 mRNA Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 37 mRNA Contract Manufacturing Market Share Forecast by End-users, 2026, 2031, 2036 (%)
  • Figure 38 Government and Academic Institutes Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 39 Government and Academic Institutes Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 40 Pharmaceutical Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 41 Pharmaceutical Companies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 42 Biotech Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 43 Biotech Companies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 44 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 45 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 46 mRNA Contract Manufacturing Market Share Forecast by Region 2026, 2031, 2036 (%)
  • Figure 47 mRNA Contract Manufacturing Market by Region, 2026-2036 (US$ Bn, AGR %)
  • Figure 48 North America mRNA Contract Manufacturing Market Attractiveness Index
  • Figure 49 North America mRNA Contract Manufacturing Market by Region, 2026, 2031, 2036 (US$ Million)
  • Figure 50 North America mRNA Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 51 North America mRNA Contract Manufacturing Market Forecast by Development Stage, 2026-2036 (US$ Million, AGR %)
  • Figure 52 North America mRNA Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 53 North America mRNA Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 54 U.S. mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 55 Canada mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 56 Europe mRNA Contract Manufacturing Market Attractiveness Index
  • Figure 57 Europe mRNA Contract Manufacturing Market by Region, 2026, 2031, 2036 (US$ Million)
  • Figure 58 Europe mRNA Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 59 Europe mRNA Contract Manufacturing Market Forecast by Development Stage, 2026-2036 (US$ Million, AGR %)
  • Figure 60 Europe mRNA Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 61 Europe mRNA Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 62 Germany mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 63 UK mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 64 France mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 65 Italy mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 66 Spain mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 67 Russia mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 68 Rest of Europe mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 69 Asia Pacific mRNA Contract Manufacturing Market Attractiveness Index
  • Figure 70 Asia Pacific mRNA Contract Manufacturing Market by Region, 2026, 2031, 2036 (US$ Million)
  • Figure 71 Asia Pacific mRNA Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 72 Asia Pacific mRNA Contract Manufacturing Market Forecast by Development Stage, 2026-2036 (US$ Million, AGR %)
  • Figure 73 Asia Pacific mRNA Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 74 Asia Pacific mRNA Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 75 Japan mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 76 China mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 77 India mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 78 Australia mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 79 South Korea mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 80 Rest of Asia Pacific mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 81 Latin America mRNA Contract Manufacturing Market Attractiveness Index
  • Figure 82 Latin America mRNA Contract Manufacturing Market by Region, 2026, 2031, 2036 (US$ Million)
  • Figure 83 Latin America mRNA Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 84 Latin America mRNA Contract Manufacturing Market Forecast by Development Stage, 2026-2036 (US$ Million, AGR %)
  • Figure 85 Latin America mRNA Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 86 Latin America mRNA Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 87 Brazil mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 88 Mexico mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 89 Argentina mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 90 Colombia mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 91 Rest of Latin America mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 92 MEA mRNA Contract Manufacturing Market Attractiveness Index
  • Figure 93 MEA mRNA Contract Manufacturing Market by Region, 2026, 2031, 2036 (US$ Million)
  • Figure 94 MEA mRNA Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 95 MEA mRNA Contract Manufacturing Market Forecast by Development Stage, 2026-2036 (US$ Million, AGR %)
  • Figure 96 MEA mRNA Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 97 MEA mRNA Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 98 GCC mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 99 South Africa mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 100 Rest of MEA mRNA Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 101 AGC Biologics: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 102 AGC Biologics: Regional Market Shares (%), 2025
  • Figure 103 AGC Biologics: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 104 AGC Biologics: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 105 AGC Biologics: Regional Market Shares (%), 2025
  • Figure 106 AGC Biologics: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 107 BioCina Pty Ltd.: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 108 BioCina Pty Ltd.: Regional Market Shares (%), 2025
  • Figure 109 BioCina Pty Ltd.: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 110 Biomay AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 111 Biomay AG: Regional Market Shares (%), 2025
  • Figure 112 Biomay AG: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 113 Bio-Synthesis, Inc.: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 114 Bio-Synthesis, Inc.: Regional Market Shares (%), 2025
  • Figure 115 Bio-Synthesis, Inc.: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 116 Catalent, Inc. (Novo Holdings): Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 117 Catalent, Inc. (Novo Holdings): Regional Market Shares (%), 2025
  • Figure 118 Catalent, Inc. (Novo Holdings): R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 119 Curia Global, Inc.: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 120 Curia Global, Inc.: Regional Market Shares (%), 2025
  • Figure 121 Curia Global, Inc.: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 122 Danaher Corporation (Aldevron): Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 123 Danaher Corporation (Aldevron): Regional Market Shares (%), 2025
  • Figure 124 Danaher Corporation (Aldevron): R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 125 Evonik Industries AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 126 Evonik Industries AG: Regional Market Shares (%), 2025
  • Figure 127 Evonik Industries AG: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 128 Kaneka Eurogentec S.A.: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 129 Kaneka Eurogentec S.A.: Regional Market Shares (%), 2025
  • Figure 130 Kaneka Eurogentec S.A.: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 131 Lonza Group AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 132 Lonza Group AG: Regional Market Shares (%), 2025
  • Figure 133 Lonza Group AG: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 134 Recipharm AB: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 135 Recipharm AB: Regional Market Shares (%), 2025
  • Figure 136 Recipharm AB: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 137 Samsung Biologics Co., Ltd.: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 138 Samsung Biologics Co., Ltd.: Regional Market Shares (%), 2025
  • Figure 139 Samsung Biologics Co., Ltd.: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 140 Thermo Fisher Scientific Inc. (Patheon Pharma Services): Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 141 Thermo Fisher Scientific Inc. (Patheon Pharma Services): Regional Market Shares (%), 2025
  • Figure 142 Thermo Fisher Scientific Inc. (Patheon Pharma Services): R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 143 TriLink BioTechnologies (Maravai LifeSciences): Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 144 TriLink BioTechnologies (Maravai LifeSciences): Regional Market Shares (%), 2025
  • Figure 145 TriLink BioTechnologies (Maravai LifeSciences): R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 146 Wacker Biotech GmbH: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 147 Wacker Biotech GmbH: Regional Market Shares (%), 2025
  • Figure 148 Wacker Biotech GmbH: R&D, 2022-2025 (US$ Million, AGR %)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!